Immunocore (IMCR) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.02
- EPS estimate
- $0.01
- EPS surprise
- −306.19%
- Revenue surprise
- +5.03%
- Revenue
- $115.9M
- Revenue estimate
- $110.4M
- Reported
- Aug 6, 2026
Immunocore reported Q2 2026 results on August 6, 2026. It posted a loss of $0.02 per share against an expected profit of $0.01, a 306.19% miss. Revenue was $115.9 million, 5.03% above the $110.4 million estimate. Compared with Q2 2025, the loss narrowed from $0.20 per share, and revenue rose about 18% from $98.0 million.
Revenue has grown strongly across the table, from $8.0 million in Q3 2021 to the Q2 2026 high of $115.9 million. Annual revenue rose about 81% from $171.8 million in 2022 to $310.2 million in 2024. Earnings have swung between small profits and losses: annual losses were $1.12 per share in 2022, $1.15 in 2023 and $1.02 in 2024, with profitable quarters in Q3 2022, Q3 2023, Q3 2024 and Q1 2025. The table has no rows for Q3 2025 or Q1 2026, so 2025 cannot be totalled. Immunocore beat the EPS estimate in 10 of the 18 quarters shown.
Q3 results came between November 6 and November 10 in each of the four years shown, which points to early November 2026. It will show whether revenue keeps rising and whether the quarter ends in a profit or a loss.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | $0.01 | −$0.02 | −306.19% | $115.9M | SEC |
| Q4 2025 | Feb 25, 2026 | −$0.21 | −$0.60 | −183.42% | $104.5M | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.14 | −$0.20 | −45.77% | $98.0M | SEC |
| Q1 2025 | May 7, 2025 | −$0.38 | $0.10 | +126.33% | $93.9M | SEC |
| Q4 2024 | Feb 26, 2025 | −$0.23 | −$0.47 | −107.60% | $84.1M | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.34 | $0.17 | +149.55% | $80.2M | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.48 | −$0.23 | +51.67% | $75.4M | SEC |
| Q1 2024 | May 8, 2024 | −$0.37 | −$0.49 | −33.15% | $70.5M | SEC |
| Q4 2023 | Feb 28, 2024 | −$0.25 | −$0.40 | −61.42% | $70.2M | SEC |
| Q3 2023 | Nov 7, 2023 | −$0.35 | $0.05 | +113.99% | $63.3M | SEC |
| Q2 2023 | Aug 10, 2023 | −$0.39 | −$0.37 | +5.19% | $60.8M | SEC |
| Q1 2023 | May 10, 2023 | −$0.35 | −$0.43 | −23.63% | $55.1M | SEC |
| Q4 2022 | Mar 1, 2023 | $0.03 | −$0.63 | −2477.36% | $58.0M | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.28 | $0.14 | +149.03% | $46.9M | — |
| Q2 2022 | Aug 10, 2022 | −$0.73 | −$0.17 | +76.56% | $39.2M | — |
| Q1 2022 | May 11, 2022 | −$1.10 | −$0.46 | +58.38% | $27.7M | — |
| Q4 2021 | Mar 3, 2022 | −$1.08 | −$0.90 | +16.38% | $8.9M | — |
| Q3 2021 | Nov 10, 2021 | −$1.12 | −$0.93 | +17.26% | $8.0M | — |
Quarterly revenue
Frequently asked questions
When did Immunocore (IMCR) last report earnings?
Immunocore last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did IMCR beat earnings estimates?
No. Immunocore reported EPS of −$0.02 for Q2 2026 against a $0.01 estimate — a 306.19% miss.
How much revenue did IMCR report last quarter?
Immunocore reported $115.9M in revenue for Q2 2026, against a consensus estimate of $110.4M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.